Skip to main content

ViaDerma, Inc. Provides a Corporate Update

Written by Customer Service on . Posted in Public Companies.

LOS ANGELES, June 23, 2020 (GLOBE NEWSWIRE) — ViaDerma, Inc., (“Company”) (OTC Pink:VDRM), is pleased to provide this corporate update:
ViaDerma has partnered with the Brewer Group, Inc., to market a white label version of Vitastem which will be sold under the name BWell. Founded by former NFL star Jack Brewer, the Brewer Group’s portfolio of projects has included hundreds of public and private capital markets transactions, major event coordination, as well as partnerships with elite brands and influencers across multiple genres. In addition to previously announced ongoing sales discussions, the Company has entered separate negotiations with representatives from the Middle East to explore the possibility of selling Vitastem and potentially other ViaDerma products in several Middle Eastern countries.The Company filed its Attorney Letter with Respect to Current Information with the OTC Markets in conjunction with its financial report and is making some minor amendments requested by OTC Markets. Upon completion of those amendments anticipated in the coming days ViaDerma is expected to return to a current filing status on OTC Markets.Dr. Christopher Otiko, President of ViaDerma, said “I am very pleased with the progress we are making on several fronts. Medical sales are typically not quick to close and often take time to bring to fruition. We have been working on several transactions for some time and we believe some may now be in the final stages of negotiation. I hope to provide further announcements regarding those pending transactions in the near future.”Additionally, the Company has received questions in recent days regarding Dr. Otiko’s association with The Wound Pros. The Wound Pros is a medical practice specializing in wound care in which Dr. Otiko is a cofounder. The Wound Pros is completely independent of ViaDerma. Possible future synergies between the companies may be explored down the road, though there are no collaborations at this time.About ViaDerma, Inc.
ViaDerma, Inc. (OTC: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas.Any forecast of future financial performance is a “forward looking statement” under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment. Our actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements.For more information, visit: www.viadermalicensing.com
Contact information:
Investor Relations
Email: info@viadermalicensing.com
Phone: 310-374-6111

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.